Director
John’s Hopkins School of Medicine Itch Center
Baltimore, Maryland
Confronting Racial Disparities in Dermatologic Education
To further discuss the changing landscape of skin of color representation in dermatology, Christopher Bunick, MD, PhD, and Shawn Kwatra, MD, review how they have seen representation change in their own experiences.
Prospective Therapies for AD
Experts discuss prospective therapies on the horizon for atopic dermatitis (AD).
Breaking the AD Cycle
Experts offer their clinical experience on preventing patient withdrawal and breaking the atopic dermatitis (AD) disease cycle.
Body Surface Area and AD
Peter Lio, MD, FAAD, discusses how body surface area of atopic dermatitis (AD) affects topical treatment options.
Important Topical Therapy Considerations for AD
Shawn Kwatra, MD, offers important considerations for providers when utilizing topical therapies for atopic dermatitis (AD).
Topical Therapy Landscape for AD
Experts discuss the history and evolving landscape of topical steroids as therapy for atopic dermatitis (AD).
JAK Inhibitors and AD
Peter Lio, MD, FAAD, and Shawn Kwatra, MD, discuss janus kinase (JAK) inhibitors and their recent use in the treatment of atopic dermatitis (AD).
Symptoms and Severity of AD
Experts discuss the symptoms of atopic dermatitis (AD) and how disease severity may impact symptoms.
The Burden of AD on Pediatric and Adult Patients
Shawn Kwatra, MD, and Peter Lio, MD, FAAD, discuss the burden of atopic dermatitis (AD) and how it may affect pediatric or adult patients.
